Vitruvias Therapeutics recalls thyroid medication due to potential 'superpotent' concerns

Vitruvias Therapeutics Inc. has issued a nationwide recall for one lot (No. 504950) of its 30-milligram Thyroid Tablets, USP. The recall stems from concerns that the product may be 'superpotent,' potentially posing health risks to patients. The affected lot was distributed from January 2025 to September 2025, with an expiration date of September 2026. Patients should consult their healthcare provider before stopping use.